x
Loading
+ -

T3 Pharmaceuticals wins prestigious Falling Walls Venture Award

T3 Pharmaceuticals, a start-up of the University of Basel, is the winner of the Falling Walls Venture science award: Marlise Amstutz, Simon Ittig and Christoph Kasper of T3 Pharmaceuticals. (Image: University of Basel, Basile Bornand)
T3 Pharmaceuticals, a start-up of the University of Basel, is the winner of the Falling Walls Venture science award: Marlise Amstutz, Simon Ittig and Christoph Kasper of T3 Pharmaceuticals. (Image: University of Basel, Basile Bornand)

T3 Pharma, a biotech start-up company of the University of Basel with a focus on immuno-oncology, has been named “2018 Science Start-Up of the Year” by Falling Walls Venture. The award honors the scientist-entrepreneurs for their breakthrough business model in bacterial cancer therapy.

09 November 2018

T3 Pharmaceuticals, a start-up of the University of Basel, is the winner of the Falling Walls Venture science award: Marlise Amstutz, Simon Ittig and Christoph Kasper of T3 Pharmaceuticals. (Image: University of Basel, Basile Bornand)
T3 Pharmaceuticals, a start-up of the University of Basel, is the winner of the Falling Walls Venture science award: Marlise Amstutz, Simon Ittig and Christoph Kasper of T3 Pharmaceuticals. (Image: University of Basel, Basile Bornand)

The Falling Walls Conference in Berlin, Germany, annually invites the world’s leading scientists to identify trends, opportunities, and solutions for global challenges and discover international breakthrough research. Falling Walls Venture showcases the most promising research-based start-ups from all over the globe that tear down walls and overcome boundaries in their respective fields.

“We thank the jury for recognizing the medical potential of our immuno-oncology approach,” commented Simon Ittig, CEO of T3 Pharma. “Our sincerest thanks go to all our friends, partners and supporters and, particularly, to the University of Basel, who nominated us for this award,” The Falling Walls Venture Award confirms the aspirations of T3 Pharma to advance their therapy into clinical use for the benefit of cancer patients.

T3 Pharma’s engineered bacteria stimulate the immune system by delivering selected human proteins directly into cells of the tumor microenvironment. Preclinical studies in a number of tumor models demonstrated a strong impact on tumor progression as well as a durable immune-mediated memory to fight recurring tumors. The clinical development for the lead candidate has been initiated in order to assess the immunotherapy in men with a first clinical trail anticipated for the first half of 2020.

Further information

About T3 Pharma

T3 Pharmaceuticals was founded in May 2015 as a spin-off of the University of Basel, Switzerland. The company is focusing on bacteria-based therapies for the treatment of solid tumors.

Thematic focal area

To top